During the recent years, there has been a resurgence in the use of HMPs, which may be due to growing consumer dissatisfaction with conventional medicines and an increase in automedication. HMPs are those medicinal products that exclusively contain herbal drugs as ingredients (e.g., parts of plants) or pharmaceutical preparations thereof (e.g., extracts, essential oils, etc.). In the United States, a botanical product, depending upon its labeling and intended use, may be a food, a dietary supplement, a drug, a medical device (gutta-percha), or a cosmetic. With herbal supplements becoming a more popular complement to living a healthy life, the adulteration of HMPs with synthetic potent drugs is a major concern for drug regulatory agencies as they pose serious health risks. There have been many reports of adulterated herbal supplements that were claimed to be “all natural.” For example, many herbal supplements claiming to improve sexual performance and vitality were found to contain sildenafil (Viagra) [1]. In order to detect the adulterants in HMPs, Liang et al. [2] made an attempt to screen multiple herbal supplements for adulterants in one LC-MS run. The current review provides a comprehensive literature on cases of toxicity due to chemical adulterants in botanical dietary supplements from 1990 to 2015, and a review of various analytical methods used for their detection.
In addition to the most common chemical adulterants listed in regulation, the ABC adulteration problems through education rather than federal to serve as a self-regulatory mechanism for industry to address products for financial gain. This industry-funded program aspires adulteration as well as intentional adulteration of plant-based NCNPR Botanical Adulterants Program focuses on both accidental Based on the notion that adulteration of botanical ingredients the United States and global commerce, determine which official or unofficial analytical meth-ods are currently available to help detect the presence (or absence) of a suspected or known adulterant, and to provide com-ment and guidance on the relative strengths and/or weaknesses of differing analytical methods [10]. Although HMPs are used worldwide, regulations on quality assurance vary from country to country. There are four major national frameworks of regulating HMPs: United States of America, European Union (EU), Canada, and Australia. In the United States, “botanical products” are regulated as dietary supplements and do not require FDA approval unless they include a new dietary ingredient, in which case a premarket notification must be submitted to the FDA. There are also two HMPs registered as drugs in the United States under the Federal Food, Drug, and Cosmetic Act. These are Veregen® (topical catechins from green tea) for genital warts and Fulyzaq® (oral Crofelm) obtained from Sangre de Drago (latex of Croton lechleri Mull. Arg., Euphorbiaceae) for the treatment of diarrhea in AIDS patients.

In Canada, they are regulated under the Natural Health Products Regulations, which are distinct from the Food and Drugs Regulations. On the other hand, HMPs and other complementary medicines are regulated as medicines under the Therapeutic Goods Act in Australia using a risk-based approach with a two-tiered system: lower risk medicines can be listed on the Australian Register of Therapeutic Goods (ARTG), while higher risk medicines must be registered on the ARTG.

The European Union Legislation on pharmaceutical products for human use also applies, in general, to traditional herbal medicines. However, in order to overcome difficulties encountered by member states in applying pharmaceutical legislation to traditional herbal medicinal products in a uniform manner, a simplified procedure was introduced in 2004. The simplified procedure was introduced by Directive 2004/24/EC/pdf of the European Parliament and of the Council of 31 March amending as a traditional herbal medicinal product Directive 2001/83/EC on the community code relating to the medicinal products for human use. The simplified procedure allows the registration of herbal medicinal products without requiring trials of safety and efficacy, provided that there is sufficient evidence of traditional medicinal use of the product throughout a period of at least 30 years, including the 15 years in the Community. With regard to the manu-facturing of these products and their quality, application for registration of traditional herbal medicinal products have to ful-

### Table 1

<table>
<thead>
<tr>
<th>Adulterant</th>
<th># Samples Examined</th>
<th># Positive Results</th>
<th>Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sildenafil</td>
<td>81</td>
<td>28</td>
<td>Enhancing sexual performance</td>
</tr>
<tr>
<td>Famotidine</td>
<td>47</td>
<td>18</td>
<td>Digestive disorders</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>14</td>
<td>3</td>
<td>Arthritis</td>
</tr>
<tr>
<td>Promethazine</td>
<td>19</td>
<td>2</td>
<td>Tranquilizer effect or improving “health status” of old people</td>
</tr>
<tr>
<td>Diazepam</td>
<td>11</td>
<td>3</td>
<td>Dysphonia and insomnia</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>16</td>
<td>6</td>
<td>Hypertension, angina pectoris, and cardiovascular health</td>
</tr>
<tr>
<td>Captopril</td>
<td>19</td>
<td>8</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>22</td>
<td>2</td>
<td>Tracheitis</td>
</tr>
<tr>
<td>Dextromethorphan</td>
<td>22</td>
<td>4</td>
<td>Alleviation of cough and expectorant effect</td>
</tr>
</tbody>
</table>


does not require FDA approval unless they include a new dietary ingredient, in which case a premarket notification must be submitted to the FDA. There are also two HMPs registered as drugs in the United States under the Federal Food, Drug, and Cosmetic Act. These are Veregen® (topical catechins from green tea) for genital warts and Fulyzaq® (oral Crofelm) obtained from Sangre de Drago (latex of Croton lechleri Mull. Arg., Euphorbiaceae) for the treatment of diarrhea in AIDS patients.

In Canada, they are regulated under the Natural Health Products Regulations, which are distinct from the Food and Drugs Regulations. On the other hand, HMPs and other complementary medicines are regulated as medicines under the Therapeutic Goods Act in Australia using a risk-based approach with a two-tiered system: lower risk medicines can be listed on the Australian Register of Therapeutic Goods (ARTG), while higher risk medicines must be registered on the ARTG.

The European Union Legislation on pharmaceutical products for human use also applies, in general, to traditional herbal medicines. However, in order to overcome difficulties encountered by member states in applying pharmaceutical legislation to traditional herbal medicinal products in a uniform manner, a simplified procedure was introduced in 2004. The simplified procedure was introduced by Directive 2004/24/EC/pdf of the European Parliament and of the Council of 31 March amending as a traditional herbal medicinal product Directive 2001/83/EC on the community code relating to the medicinal products for human use. The simplified procedure allows the registration of herbal medicinal products without requiring trials of safety and efficacy, provided that there is sufficient evidence of traditional medicinal use of the product throughout a period of at least 30 years, including the 15 years in the Community. With regard to the manu-facturing of these products and their quality, application for registration of traditional herbal medicinal products have to ful-

All of the frameworks mentioned incorporated methods of reporting adverse events (AERs). Most people do not report adverse re-actions because they consider HMPs harmless, being “natural products.” Valuable HMPs AER information is available from sources such as Natural Medicine Watch, FDA MedWatch, Canada Vigilance Program, WHO-Uppsala Monitoring Centre, Australian Therapeutic Goods Administration, and the British Medicines and Healthcare Products Regulatory Agency (MHRA).

According to data in 2006 from the AAPCC [12], there were 972,073 exposures to pharmaceutical products resulting in adverse events (AERs). Of the adverse reactions reported, 73,364 of them were due to dietary supplements and vitamins, with 42 major outcomes and 3 deaths.

The Dietary Supplements Information Expert Committee (DSI-EC) of the Pharmacopoeial Convention (USP) conducted a review in 2008 [13] that looked over the safety guidelines and reporting systems currently in place for dietary supplements. It was found that there is a difficulty in reporting AERs because dietary supplements contain multiple ingredients, which leaves

Table 1 Common chemical adulterants in HMPs since 2004 [3–9].

<table>
<thead>
<tr>
<th>Adulterant</th>
<th># Samples Examined</th>
<th># Positive Results</th>
<th>Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sildenafil</td>
<td>81</td>
<td>28</td>
<td>Enhancing sexual performance</td>
</tr>
<tr>
<td>Famotidine</td>
<td>47</td>
<td>18</td>
<td>Digestive disorders</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>14</td>
<td>3</td>
<td>Arthritis</td>
</tr>
<tr>
<td>Promethazine</td>
<td>19</td>
<td>2</td>
<td>Tranquilizer effect or improving “health status” of old people</td>
</tr>
<tr>
<td>Diazepam</td>
<td>11</td>
<td>3</td>
<td>Dysphonia and insomnia</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>16</td>
<td>6</td>
<td>Hypertension, angina pectoris, and cardiovascular health</td>
</tr>
<tr>
<td>Captopril</td>
<td>19</td>
<td>8</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>22</td>
<td>2</td>
<td>Tracheitis</td>
</tr>
<tr>
<td>Dextromethorphan</td>
<td>22</td>
<td>4</td>
<td>Alleviation of cough and expectorant effect</td>
</tr>
</tbody>
</table>
room for contamination, substitution of herbs or botanicals, and adulteration. Along with those risks when AERs were reported, it is difficult to interpret the data because of a lack of case information, unknown manufacturers, and unknown variable patient history. The primary reporting portal for the FDA, MedWatch, again was found to receive fewer reports than Poison Control Centers and with the limited coordination between the two, this leaves the public with potential health risks. The DSI-EC concluded that there needs to be enhanced data collection approaches, improved coordination of AER surveillance programs, strengthened educational programs for both public and health care sectors, and research conducted concerning the safety of dietary supplements in order to help resolve the issue of dietary supplement AERs.

The FDA has attempted to increase AERs by taking advisory actions and lawsuits against dietary supplement manufacturers. However, their efforts seem to be insufficient. Of AERs during 2008 and 2010, there were over 1000 more cases reported to the AAPCC than the FDA [14]. This poses the question of whether coordination between the two to address this issue would be enough to bring this dilemma to the public eye and cause a change in manufacturing regulation.

In 2012, an active surveillance of dietary supplement AERs was conducted for 112 weeks, in which the pharmacies participating would ask patients getting prescriptions about their combined use of dietary supplements and prescription medications over the past 3 months and if they had any AERs [15]. Of the 2615 patients screened, 1037 of them reported use of dietary supplements Report from 2007 to 2012, 332 dietary supplement AERs were reported to the AAPCC. Of the 2615 patients screened, 1037 of them reported use of dietary supplements in combination with prescription medications. Only 15 patients of the 77 with possible AERs were available for later interview and 4 of those 15 were determined to “probably” be due to dietary supplement use. In the first case, a 19-year-old male patient with a history of depression, neuropathic pain, and delayed sleep phase disorder added melatonin to his recurrent prescriptions of citalopram, nortriptyline, and oxycodone presented what he described as severe sedation. Another patient, a 53-year-old female with asthma and symptoms of menopause and depression/anxiety, was hospitalized with jaundice and fatigue. She was diagnosed with hepatic necrosis and had been taking 13 different products, several of which were dietary supplements for weight loss along with several of her prescription medicines. The study concluded that passive surveillance was not very effective time and time again and is not a very reliable approach, and that the potential advantages of active surveillance could be the best route in finding and minimizing dietary supplement AERs. From the perspective of regulations and compliance enforcement, it is important to note that an HMP such as a dietary supplement in the United States that is adulterated with a drug is legally no longer an HMP or dietary supplement but is an unauthorized drug. This is an important distinction with regard to penalties that regulators can impose to help protect consumers from the potentially dangerous products. More information on the regulations of herbal medicinal products can be found in a review by Gupta [16].

The current review provides a comprehensive literature on cases of toxicity due to chemical adulterants in botanical dietary supplements from 1990 to 2015 and various analytical methods used for their detection.

Case Reports of Toxicity Due to Chemical Adulterants

Perhaps the greatest risk to people from HMPs is adulteration with common drugs for cases like sleep aids (clonazepam), weight loss (sibutramine and fenfluramine), diabetes (glibenclamide), and bodybuilding (steroids) products. Specifically, the product PC-SPES (a mixture of eight herbs manufactured by Botanic Lab Inc.) was used for prostate cancer. It caused a change in several genes associated with microtubule dynamics by adulteration with ethinylestradiol, warfarin, and indomethacin [8]. Dietary foods and herbal weight loss supplements have become very popular with the recent fad of staying in shape and looking healthy. Fenfluramine has now been banned by the FDA in the U.S. and in Hong Kong after reporting problems with pulmonary hypertension and valvular disease [17]. An analogue of fenfluramine, N-nitrosofenfluramine, is reported to be responsible for more than 800 hepatotoxicity cases in Japan as well as in Singapore and the United Kingdom [18–20]. The majority of patients recovered and those who did not either died or developed fulminant hepatic failure. Sibutramine was formerly approved by the FDA and is generally well tolerated. Its common side effects are headache, constipation, nausea, dizziness, dry mouth, and insomnia [21]. It is associated with high blood pressure and increased heart rate. Recently, it has been related to manic episodes, panic attacks, and mood swings [22–24]. The problems with sibutramine were also reported in Japan and Taiwan [25, 26]. Sibutramine, as mentioned previously, is a drug that has been intentionally added to slimming products as an appetite suppressant [27]. This was extremely popular in HMPs until it was banned in both Europe and the United States in 2010 for its potential cardiovascular risks or even strokes [28, 29]. Sibutramine also has the potential to interact with other medications and cause serotonin syndrome [29]. Patients from Hong Kong reported side effects after taking one of the three over-the-counter slimming products to the Hospital Authority Toxicology Reference Laboratory between 2004 and 2006. During this period, 979 patients were referred to the laboratory; however, only 42 had possible ailments related to the weight-loss products. Twenty-eight of the patients tested positive in their urine samples for fenfluramine, non-prescribed sibutramine, non-prescribed thyroid hormones, and undeclared Western weight-loss drugs. Adulterants included sibutramine and its analogue, fenfluramine and its analogue, phenolphthalein, thyroid tissues, propranolol, hydrochlorothiazide, mazindol, and caffeine [26]. Another adulteration case with Tung Shueh pills in Taiwan was of acute renal failure; although, it was not established as to which adulterant caused this adverse reaction. In Singapore, Tung Shueh pills used for pain relief were adulterated with caffeine, diazepam, indomethacin, and prednisolone, which can cause mental depression, bone loss, spontaneous fractures, intestinal bleeding, and even coma [3]. Additionally, an herbal supplement, Gu Ben Wan, used to treat dry cough was found to contain six undeclared adulterants [3].

With the increased popularity of using herbal supplements in the last few years, countries are becoming increasingly aware of the need to screen these drugs. For example, in the FDA Tainted Supplements Report from 2007 to 2012, 332 dietary supplement products were adulterated. Of these, more than 95% were sexual performance enhancement products [29]. Many herbal supplements claiming to have sexual enhancement properties are adulterated with PDE-Sis like sildenafil, tadalafil, and vardenafil. There are more than 50 analogues of these products with minor
structural modifications that may have the same desired pharmacological properties [30,31]. Since many of these analogues are difficult to detect and never went through the thorough preclinical and clinical studies needed for market authorization, their toxicity is unknown, thus becoming a serious safety concern to the public [31]. Gilard et al. [32] believe that the combination of 1H NMR and mass spectroscopy is the easiest method to detect these analogues. In their study, they analyzed 150 sexual enhancement herbal supplements that claimed to be “pure” and found that 61% of them were adulterated with at least one PDE-5i. Additionally, eight herbal supplements contained sexual dysfunction drugs (flibanserin, yohimbine, phenolamine) or hormones (DHEA, testosterone). It was found that 59 of the 92 adulterated products contained only one drug, while the other 33 contained two or more adulterants. The most frequent adulterants found were sildenafil analogues, which accounted for 51% of the adulterants used, followed by tadafalit.

A screening carried out by the Health Science Authority in Singapore from 1990 to 2001 found adulterants in 41 of 3320 Chinese medicinal products, of which 19 contained synthetic drugs. Of these, 12 of them claimed to treat sexual dysfunction in males by intentionally using adulterants such as sildenafil, tadafalit, and vardenafil [3,33]. These findings provide the necessary evidence of why herbal supplements should be screened in order to keep the customers safe from unintended side effects. Cohen et al. [34] at the Harvard University Medical School conducted a recent study on weight-loss and sports enhancement herbal products containing *Acacia rigidula* Benth. (Fabaceae), in which 11 of the 21 products tested contained BMPEA, a synthetic isomer of amphetamine. BMPEA has been used in dietary supplements since 2010, but its safety and efficacy in humans have not been studied. Research on the association of *A. rigidula* and BMPEA was first done in the 1960s and then again in the 1990s. The initial research concluded that *A. rigidula* contained large amounts of methamphetamine and mescaline (both Schedule 1 controlled substances). More recent research shows that there were significant errors in the initial research, likely due to aggressive extraction and older analytical techniques, and that either these products were not found in *A. rigidula* or they were in such low quantities they would have almost no effect. The Harvard research team released a case report on a 53-year-old woman who suffered a hemorrhagic stroke, which they concluded was likely due to a combination of a BMPEA-containing supplement the woman had been taking and exercise [35]. The publication of this study followed a major investigation conducted by the New York Attorney General on failed DNA barcode tests for identity in herbal dietary supplement products. Possibly, at least partially, in response to external pressure from the New York Attorney General and calls from three United States Senators, the FDA sent letters to five companies warning them about BMPEA in their products and also banned the sale of BMPEA. The lead author of the Harvard Study, Pieter Cohen, said that the FDA’s action was a step toward the right path but it was a small one. Cohen proclaimed that the letters only dealt with companies who openly labeled BMPEA on their products, rather than addressing companies that solely label *A. rigidula* on their products and conceal the spiking with BMPEA [35].

A study of 489 cases from the U.S. Poison Control Centers was conducted in the United States over one year associated with adverse reactions to dietary supplements [36]. The cases were selected using a multistep review process leading to at least a 50% certainty that the negative events were associated with dietary supplements; however, 93% of the side effects were considered mild in all age groups and on organ systems. A more recent one-year study from the California Poison Control System reported two-thirds of the adverse reactions were associated with dietary supplements and a majority of them were classified as moderate to serious. The most common contaminants were caffeine, yohimbine, bitter orange, and gentian. Some adverse reactions involved blood coagulation disorders attributable to fish oil, ginkgo, and vitamin E [36].

The China Food and Drug Administration (CFDA) released documentation in 2015 explaining recent ginkgo production containing adulterants. It was discovered that the pharmaceutical companies substituted 3% hydrochloric acid for ethanol and water [37]. Another case claims the manufacturers used purchased ginkgo extract from eight other companies to produce ginkgo supplements. These pharmaceutical companies along with some others were forced to discontinue their products after these discoveries of false advertisement were made public.

In one study, Mathon et al. [38] found HPTLC coupled with UV densitometry a suitable technique for both the identification and quantification of sibutramine in dietary supplement products. This study was conducted over a two-year period in which around 50 dietary supplements were purchased on the Internet. They bought 39 products in 2010 when sibutramine was initially banned from markets and in 2012 to see if the manufacturers were complying with this ban. The product label did not mention sibutramine and the products were advertised as natural weight-loss products. Of the 39 products bought in 2010, 17 (44%) of them were found to contain the adulterant sibutramine in quantities ranging from 3 to 35 mg per capsule. This shows that someone could have taken three times the recommended dosage in one capsule before it was banned in Europe [39]. From the 13 products purchased in 2012, 9 (69%) of them contained sibutramine. The quantities ranged from trace amounts to 10 mg per capsule. Even though the concentration of sibutramine in natural weight-loss products has decreased, the percentage of products in which it is found has increased, which poses a threat to customers. This also shows that the manufacturers were not complying with the FDA ban.

Drugs that have herbal formulations for body strength, memory, sexual potency, weight loss, and diabetes with very high sales have been known to be intentionally adulterated by the manufacturers. For example:

- Poon et al. [40] analyzed “Chang Qing Chun” weight-loss capsules and found the presence of significant quantities of undeclared caffeine, antrhaquinones, riboflavin, nicotinamide, pyridoxine, N-nitrosobenfuramino, fenfluramine, sibutramine, phenolphthalein, and propranolol. Another herbal formulation called “Qing Zhi Mei” was also found to contain caffeine, antrhaquinones, ephedrine, fenfluramine, propranolol, and phenolphthalein as well as animal thyroid tissue.

- A product named Qnexa claimed to help people lose weight and lower blood pressure, blood sugar, and cholesterol. However, the FDA banned it in 2010 because of its dangerous side effects [41].

Spice, an herbal mixture found in several European nations, became available in 2004 as a legal alternative to cannabis, which substantially increased its popularity [42]. Spice Silver, Spice Gold, Spice Diamond, Yucatan Fire, and Smoke are common names of Spice’s early use as incense. There were several herbs labeled as ingredients, but no synthetic additives; additionally, they claimed to have the same effects as cannabis without an
GFSE has been marketed as a natural product for over 30 years. Asihuri Plus Forte is used for joint and nerve pain. It was found that Saurean Fong Sep Lin is promoted for back pain and injury. It is claimed that Jianbu Huqian Wan also claimed to help consumers with their health issues. Ginseng She Lian Wan, which claimed to help alleviate joint pain, arthritis, and gout, is now banned by the FDA as its labs confirmed that it contains dexamethasone, a corticosteroid, and chlorpheniramine. The FDA is not aware of adverse reactions to this product; however, it is known to have complications with withdrawals from corticosteroids. Dexamethasone is also known to impair immunity, increase blood sugar, and cause muscle and psychiatric complications.

Jianbu Huqian Wan also claimed to help consumers with their joint pain and was found to contain dexamethasone, chlorpheniramine, and furosemide. Chlorpheniramine is an antihistamine that can cause drowsiness. Furosemide is a potent diuretic that can cause dehydration and electrolyte imbalance that may lead to seizures, kidney damage, gastrointestinal problems, and coma.

Saurean Fong Sep Lin is promoted for back pain and injury. It is unequivocally adulterated with dexamethasone and cyproheptadine. Cyproheptadine is an antihistamine that can cause drowsiness.

Ashihuri Plus Forte is used for joint and nerve pain. It was found to contain dexamethasone and phenylbutazone. Phenylbutazone is an NSAID that is discontinued in the United States due to its potential of severe bone marrow toxicity. This side effect is reversible in some cases, but in others it can be lethal.

GFSE has been marketed as a natural product for over 30 years. The claimed ingredient is an extract of grapefruit seeds, but has been advertised today as a natural, antimicrobial agent for eczema, acne, cold sores, athlete’s foot, thrush, colds, gastrointestinal disorders, sore throat, vaginal infections, gingivitis, and allergies. Some studies have shown that GFSE products contain microbicidal compounds such as benzalkonium chloride, benzethonium chloride, triclosan, and methyl p-hydroxybenzoate. The FDA has distributed Warning Letters to drug companies about the effects of GFSE products sold as dietary supplements [47].

In a study conducted by Geller et al. [48] at the Centers for Disease Control and Prevention, there were more than 23,000 emergency room visits and 21,544 hospitalizations annually from adverse reactions caused by the adulteration of dietary supplements. The supplements observed to cause these hospitalizations were primarily from multivitamins and supplements for iron, sleep, weight loss, and anxiety. The most common symptoms were chest pain and tachycardia associated with weight loss and bodybuilding supplements. Choking and difficulty swallowing were associated with multivitamins, but the majority of these cases were seen in elderly people.

Analytical Techniques for Detection of Chemical Adulterants

Vaclavik et al. [49] published a review discussing the major MS methods based on publications from 1997 to 2014. The methods included were liquid chromatography, gas chromatography, flow injection, capillary electrophoresis, and ambient mass spectrometry for the screening of adulterants. The review then describes in detail the combinations of methods used and the findings from the authors. Vaclavik et al. [49] cover most of the screening techniques, however, they do not mention the newer techniques of TLC-SERS and ATR-IR. These methods were verified with some type of MS, but they omit MS from the technique and are intended for on-site screenings. The techniques covered in the current review were searched in publications in SciFinder from 2003 to 2015 (Table 2).

Mass spectrometry-based techniques

LC-MS has become a key method in identifying compounds in HMPs and other botanical products, as it is capable of providing data on both the quantities and structures. This method was used for the detection of an extremely polar hypoglycemic drug, metformin, found in HMPs [54]. This concluded with a more separated and pure sample of metformin from matrix interferences. Another method utilized UHPLC, which distinguished 57 pharmaceuticals [55]. UHPLC has also been used to separate steroids, hypoglycemic products, and antihypertensive agents in dietary supplements, 17 non-opioid analgesics, and NSAIDs [56–58]. Ionization analysis of dietary supplements can be reviewed in a positive or negative mode. Negative ESI has been run to determine...
the presence of thiazide-type and other diuretics, estrogens, NSAIDs, salicylic acid, and valproic acid [56,59,60]. To obtain more data, the MRM fragment data of the compounds has been tested on anabolic steroids in various supplements [61]. To detect further selectivity, LC-QTOF-MS screenings of Indian aphrodisiac HMPs have found sildenafil, tadalaif, and vardenafil. A strategy for utilizing a more intense bioaffinity mass spectrometry has been used for the identification of anabolic steroids in HMPs [62,63].

The applicability of GC-MS is determined by the volatility and thermal stability of analytes. A faster technique for GC-MS was discovered for the detection of sildenafil, tadalaif, and vardenafil in food and herbal products. A GC-MS method was successfully used for the screening of 134 pharmaceuticals in patent medications in China [64].

Flow injection-mass spectrometry (FI-MS) is a technique that allows for the sample being placed in a carrier to move directly into the atmospheric pressure interface of the mass spectrometer. This method has been tested on multiple PDE-5is in dietary supplements including sildenafil, tadalaif, and vardenafil [65]. Another study was carried out for weight-loss drugs including sibutramine and its analogues [66]. Tests were positive on comparing the ratios of referenced standards with the MRM calculations of the adulterants.

 Ambient mass spectrometry is beneficial because it provides information very quickly using minimal sample preparation. A study using ambient mass spectrometry and direct analysis in real time (DART) has been conducted for the analysis of 7 hypoglycemic drugs in HMPs used to treat type 2 diabetes mellitus [67]. Another study utilized desorption corona beam ionization mass spectrometry (DCBI-MS) for analysis on 16 weight-loss regimens that included fenfluramine, phenolphthalein, and sibutramine and its analogues [68].

While using this method, two of the most common adulterants, sildenafil (Viagra) and famotidine, found in Chinese herbal supplements were looked at in further detail. Sildenafil is found in herbal supplements that claim to improve sexual performance. Eighty samples under suspicion of being adulterated with this drug were tested using this method and it was found that 28 contained sildenafil. The State Drug Administration of China used the HPLC method for testing the same drugs and found 34 adulterated supplements, but the method proposed by Liang et al. [2] proved that 6 of them were false positives. The second study aimed at finding the adulterant famotidine, which is found in supplements that claim to be useful in gastrointestinal distress and gasosis. Liang et al. [2] tested 40 samples and found 18 of them to be positive for famotidine.

Capillary electrophoresis
CE-MS consists of electrokinetic separation of analyte groupings according to the ion mobility in an electric field. Capillary zone electrophoresis and micellar electrokinetic chromatography (MEKC) along with an ESI source was used to analyze 16 HMPs individually for the following analytes: NSAIDs, analgesics, antipyretic stimulants, and anxiolytics [69]. A more recent method of CE-MS was introduced for more adequate testing of adulterants in weight-loss dietary supplements.

Millions of people are affected by obesity worldwide. To help fight this, there are thousands of weight-loss supplements and diets that are advertised, some of which are herbal medicinal products. According to Brazilian legislation, all HMPs should contain exclusively raw vegetables and no synthetic drugs [70]. Brazillian studies have found HMPs adulterated with anorexic drugs (amfepramone and fenproporex), antidepressants (fluoxetine), and anxiolytics (benzodiazepines) [71,72]. Some side effects reported caused by these adulterants includes chest pain, nausea, insomnia, fatigue, palpitations, and headache [73]. Sibutramine has also been banned in Brazil, due to its presence in “natural” weight-loss products [74].

CE normally employs UV detection for analysis and is sometimes coupled with MS. CE has gained a reputation for its success in the separation of adulterants. Contactless conductivity (C4D) is capable of selectively screening amfepramone, fenproporex, sibutramine, fluoxetine, buropion, sertraline, paroxetine, and flurazepam in HMPs; it can also separate cationic species. This hypothesis was tested in 106 samples in approximately half of Brazil’s pharmacies [75].

CE is a beneficial and simple method because it is rapid, inexpensive, and requires fewer quantities of the samples. Caffeine (stimulant), furosemide (diuretic), and NEP and EP (stimulant, decongestant, and anorexics) have been found in putative botanical products, but their side effects are unpredictable in different people and in different doses [76].

Hyphenated techniques
Schramek et al. [77] screened multiple identical samples of herbal supplements for PDE-5is using LC-DAD and LC-MS. They found 14 compounds with the same pyrazolopyrimidine structure similar to sildenafil. Seven of these have already been previously published (piperezanofil, isopiperzionalofil, oxoacetildenafil, (Z)-(E)-dichlorodienofil, gendanofil, and hydrohomoacetildenafil) [78]. The parent structure of sildenafil as well as its five analogues was also detected using LC-MS, UV, and NMR spectrometric methods [79].

Liang et al. [2] proposed a method of LC/MS/MS because it is both rapid and reliable for the screening of complex matrices in a single run. Previously proposed methods such as HPLC, GC/MS, and LC/MS were said to be inadequate in their reliability for high-throughput screening because many herbal supplements contain a mixture of herbs and other products, and the complexity of the herbal supplements will interfere with spectroscopic and chromatographic assays. Liang et al. [2] used MRM to screen a mixture of compounds simultaneously by using three selected transitions for each compound to improve reliability on relative peak areas. Transitions are monitored under Optimal Collision Energy (OCE) and the analysis was sped up without compromising the mobile phases and also by having high selective MS/MS to ensure specificity [79]. When the LC/MS/MS method was tested, 74 of 200 samples tested positive for adulterants without false positives or false negatives.

Balayssac et al. [80] conducted a screening of nine sexual enhancement herbal dietary supplements that were intended to be marketed in Southern Europe. A combination of NMR and MS was used to detect PDE-5is. Five PDE-5is were detected as adulterants: thiosildenafil (THIO), sildenafil (SILD), tetrahydropalmatine (THP), phenolamine (PHE), and a newly detected adulterant, PP-THHS. IR spectroscopy as a supplement to NMR and MS was used for the determination of the identity of PP-THHS. Eight of the nine sexual enhancement herbal dietary supplements unequivocally were found to be adulterated with PDE-5is, four were found to contain PP-THHS, one thiosildenafil, two contained both sildenafil and tetrahydropalmatine, and one was found to contain phenolamine.
Johansson et al. [81] created an analytical platform using LC-QTOF-MS in combination with NMR spectroscopy to analyze unknown compounds in various types of herbal supplements. The World Health Organization (WHO) found that there were counterfeit products that had been falsely labeled and they either did not contain the APIs stated, or contained too little or too much, or had a different API all together [82]. These findings pose a serious health risk to consumers since some falsely identified supplements have caused deaths in the past. Martino et al. [83], in a review, discussed colorimetry, TLC, GC, HPLC, MS, and different vibrational spectroscopic methods.

A separate study also proved that ¹H NMR was a beneficial tool in identifying and quantifying adulterants [84]. A more difficult task, rather than just identification and quantification, is determining whether a substance is legitimate or counterfeit. One successful study that was able to achieve this using chemometrics and chromatographic fingerprinting methods based on HPLC-UV data to determine counterfeit erectile dysfunction drugs [85].

Liquid chromatography for the LC-QTOF-MS procedures was performed on a 1290 Infinity UHPLC equipped with a diode array detector. Quantification and identification for QTOF-MS used a database that was developed in-house. In the beginning, it should be stated that it contained around 4200 pharmaceutical compounds. For compounds that were more similar to the parameters in the QTOF-MS database, more in-depth information was required. Other in-house databases were created for this purpose that contained information like MS/MS data, retention times on the chromatographic columns for specific substances, and investigations of UV spectra. Five standard NMR experiments were used: ¹H, ¹³C attached proton test, 2-dimensional gradient H,H-COSY, 2D gradient H,H-HSQC, and 2D gradient H,C-HMBC. The experiments were conducted over a five-year period with 150 to 250 samples analyzed each year. The most difficult part of this process was deciding how to start screening for APIs for various samples. A combination of LC-QTOF-MS and NMR was proven to be very effective when screening for adulterants in pharmaceutical tablets and capsules, herbal food supplements, ointments, and creams. The procedure was made easiest when LC-QTOF-MS only generated one peak, the MS spectrum generated only one hit in the database search, LC retention time with a reference compound and/or UV spectrum confirmed the hit, and identification was made with MS. NMR can readily confirm the identity and can be followed up with quantitative determination of the adulterant content in the product by qNMR [86,87]. However, this was not the case most of the time and other routes had to be taken in order to identify the adulterants. Thus, NMR can be applied directly when the adulterant in question needs to be found by using the spectra added to the NMR library created. This database has been divided into two different sub-databases: (1.) slimming products and (2.) products for pain. A screening procedure was performed on each of these product types and searched for adulterants within them.

1. In weight-loss products, a collaboration with Swedish Customs was made and 43 supplements were screened using LC-QTOF-MS. Of them, 21 were adulterated with products such as sibutramine, orlistat, sildenafil, fluvastatin, and yohimbine.

2. When searching for products that treated pain, Fortodorol was one of the first and was advertised as an herbal product. There were reports of liver damage due to this product that suspected the presence of NSAIDs. The API found in Fortodorol was nimesulide, which is a COX-2 inhibitor and is not approved in many countries because of a hepatotoxicity risk.

The above method proves that LC-QTOF-MS and NMR used in conjunction can accurately identify and quantify adulterants present in all types of herbal supplements. This process has been applied to thousands of samples and can usually be performed without using reference samples, which makes it a more convenient method.

Deconinck et al. [88] have devised a way to use ATR-IR to detect sibutramine at inspection sites. ATR-IR is unique because unlike other more common methods, there is no sample preparation, which allows for the screening of samples both in the solid and liquid form. Using this method, Deconinck et al. [88] screened 125 dietary supplements that were suspected to contain sibutramine. After screening, they used chemometric methods to evaluate the data. Combinations of exploratory and modeling methods were used. It was found that principle component analysis (PCA) using the Yenyukov index for exploratory and k-Nearest Neighbors (k-NN) for modeling obtained the most accurate and reliable results. The k-NN showed a correct classification rate (CCR) of 83% and only three samples were misclassified when an external validation was done. All of the misclassified samples were found to be false positives. Their results concluded that ATR-IR and chemometrics were able to detect sibutramine in adulterated food supplements and powders. This technique was able to detect sibutramine in concentrations of 3 mg to 30 mg in powders ranging from 300 mg to 20 g. This technique is well adapted for inspections because there is no sample preparation and the instruments used are compact.

Lorcaserin is a drug that is used as an appetite suppressant for weight loss. The FDA approved it in 2012 [89]. Due to its side effects like euphoria and hallucinations at higher doses, lorcaserin is now listed as a Schedule IV controlled substance [90]. “Lose quickly” is a French dietary supplement that is available in capsule formulation. It was subjected to ultra-performance liquid chromatography (UPLC)-MS, IR, and NMR analyses. The NMR indicated the presence of suspected adulterants; therefore, flash chromatography was utilized to further study the sample. The UPLC, ¹H and ¹³C NMR, and MS signals indicated a heterocyclic chemical compound made up of a benzene ring attached to an azapane ring that was unequivocally lorcaserin. The qNMR technique is used for quantifying components of complex mixtures. It is useful in this scenario because it does not require a reference standard. The calculated amount of lorcaserin in each capsule of “Lose quickly” was 6.6 ± 0.8 mg per day, while the recommended dosage of the drug Belviquor (lorcaserin hydrochloride) is 10 mg twice per day [91]. Belviquor is used for serious weight management with a calorie-oriented diet. In spite of the small amount of lorcaserin present in “Lose quickly”, the public was using without knowing that it contained a harmful chemical compound. Thus, an overdose of “Lose quickly” could lead to unexpected overdoses of lorcaserin.

Gold Nine Soft Capsules is a Chinese herbal medicine that is used to treat hypertension. Liquid chromatography-high-resolution mass spectrometry (LC-HRMS) was utilized for the identification of compounds in this HMP. The use of liquid chromatography, mass spectrometry, solid-phase extraction, and nuclear magnetic resonance (LC-MS-SPE/NMR) following LC-HRMS allowed for an analysis of isolated adulterants in this herbal product. LC-MS-SPE/NMR is beneficial as it allows for the rapid identification of adulterants without the need for reference standards. Amlodipine (blocks calcium channels), indapamide (diuretic), and valsartan (angiotensin II receptor antagonist) were discovered as components of Gold Nine Soft Capsules [92]. It was determined...
that each casing of the Gold Nine Soft Capsules contained 1.52 ± 0.10 mg of amlodipine, 1.52 ± 0.07 mg of indapamide, and 40.46 ± 2.44 mg of valsartan. It is possible that the significant amount of valsartan could be due to the insolubility of the oily formulation and absorption on to the gelatin shell of the capsule. The Gold Nine Soft Capsules were tested in hypertensive rats. Additionally, a combination of amlodipine, indapamide, and valsartan was tested in an identical population. Both treatments showed the same result: brief increased heart rate. Each of the three drugs was tested individually for the lowering of blood pressure and to see specific adverse reactions. The doses of valsartan administered to the rats had the most significant effect on blood pressure. In conclusion, the three drugs in combination will produce a longer lasting rather than a stronger effect in hypertensive patients.

Thin-layered-based analytical techniques
In a study funded by the Chinese government, Zhu et al. [93] developed a rapid and reliable TLC-SERS technique for the determination of adulterants in herbal supplements. The preliminary experiment for this technique was carried out in 2013 and the technique enabled qualitative identification of adulterants in antidiabetic herbal supplements with few false-positive results. The TLC technique was chosen because of its already well-established history and the benefits of its simple operation, the low cost for drug quality verification, its high-throughput potential, and its ease of portability [94,95]. Although TLC has all of these benefits, this technique requires reference chemicals and a chromogenic agent. During the experiments conducted by Zhu et al. [93], four reference chemicals were chosen from the drug class’s biguanide and thiazolidinedione. The reference chemicals were obtained from the National Institute for Food and Drug Control of China: phenformin hydrochloride (PHE), metformin hydrochloride (MET), ROS, and pioglitazone hydrochloride (PIO). Raman spectra were obtained using a portable Raman spectrometer (BWS415) at an excitation wavelength of 785 nm. Two different types of TLC plates, silica gel 60-F254 plates and high-performance silica gel 60-F254 plates, were used. Spots were visualized by the use of an UV lamp (WFH-203B) at 254 nm and UV-visible (UV-VIS) absorbance spectra of silver colloids were collected using a Varian Cary 100 Conc spectrometer. Microwave heating for the preparation of silver colloids was best suited for the experiment as it enhanced all four of the reference compounds when applied. The simulated experiment proved that the TLC-SERS technique was able to detect trace amounts of adulterants even if the chromatographic spots of the analytes were not visible in UV light and/or the scattering coefficient was low. It was noted, however, that in order to obtain sufficient and definitive identification from Raman peaks, at least four or five peaks specific to each drug compound were needed. To further test this technique, Zhu et al. [93] applied it to 12 botanical products provided by the Shandong Institute for Food and Drug Control. The TLC-SERS technique determined that three samples were adulterated with ROS, while one sample was adulterated with both ROS and phenformin hydrochloride (PHE). These results were verified by liquid chromatography-triple quadrupole mass spectrometry (LC-MS-MS).

Cai et al. [96] have developed a rapid screening technique using TLC and HPLC coupled with PDA-MS (HPLC-PDA-MS) for the simultaneous determination of eight PDE-5is. These eight PDE-5is included sildenafil, hongdenafil, homosildenafil, hydroxyhydro sildenafil, vardenafil, pseudovardenafil, tadalafil, and aminotadalafil. The TLC and HPLC-PDA-MS techniques were applied in this study to rapidly screen and determine the presence of PDE-5is in 36 commercial Chinese Herbal supplements. These techniques were proven successful, the TLC technique significantly reduced the analysis time, and the HPLC-PDA-MS technique had good sensitivity, precision, and accuracy. The TLC technique can be used effectively for rapid screenings of PDE-5is in suspected adulterated HMPs. UV absorption spectra overlay can be used to identify the PDE-5is. The HPLC-PDA-MS and HPLC-UV techniques were both tested for the screening and identification of the eight PDE-5is used to adulterate HMPs. The identification of the adulterants in herbal supplements was determined by comparing retention times, UV spectra, and MS spectra of reference PDE-5is with those extracted from the herbal supplements. Ten of thirty-six herbal supplements marketed as aphrodisiacs were found to contain PDE-5is as adulterants.

Lv et al. [97] also developed a method similar to that developed by Zhu et al. [93] in which both used TLC-SERS to detect adulterants, but there were a few notable differences. Lv et al. developed their technique to the alkaloid ephedrine and its analogues used to adulterate weight-loss botanical products. EP, PSE, MEP, and NEP were the most popular adulterants used in weight-loss HMPs in their experiments, but they are also used clinically to treat respiratory ailments (i.e., asthma, colds, influenza, rhinitis). Although some of these drugs are used clinically, they have been known to have adverse side effects like cardiovascular problems, significant sympathomimetic activity, and central side effects. However, ephedrine products pose a greater risk to athletes because they act like an adrenaline boost and have the potential to hide the signs of fatigue. These products increase metabolism, increase blood pressure, and put added stress on the heart, which could allow athletes to push beyond their normal limits. This technique was developed for the direct identification of trace adulterants in HMPs without requiring reference substances. An analytical method was developed with eight common peaks shared by the four ephedrine analogues (EP, PSE, MEP, NEP) for a rapid and reliable detection. The four ephedrine analogues used as reference chemicals to develop the analytical method were purchased from the Chinese National Institutes for Food and Drug Control. In this experiment, only the high-performance glass silica gel, thin-layer chromatography scanner, and UV analyzer (WFH-203B) at 365 nm were used. The Raman spectra were recorded on a portable Raman spectrometer (BWS415) at 785 nm and an Agilent Technologies 1290 Infinity-6538 UHD Accurate-Mass UPLC-QTOF/MS verified the results. An important aspect that differed in this experiment was the use of DFT. DFT provides a relatively efficient and unbiased tool to compute the ground state energy in realistic models of bulk materials and their surfaces. The DFT was applied to Raman spectra obtained from EP, PSE, MEP, and NEP. The DFT found that the four analogues shared eight common peaks, which helped illuminate one of the four specific adulterants illegally added to HMPs when scanning on site with no reference materials available. Results prove that the TLC-SERS technique proposed by Lv et al. [97] is able to quickly and reliably detect the four ephedrine analogues as adulterants in HMPs or botanical products in trace amounts with no reference materials available. This technique was applied to nine samples of weight-loss HMPs provided by the Shandong Institute for Food and Drug Control. The outcomes showed that two samples were adulterated, one with PSE and the other with NEP. The TLC-SERS technique results were confirmed by UPLC-QTOF/MS.

Calahan J et al. Chemical Adulterants in... Planta Med 2016; 82: 505–515
Conclusions

Some herbal medicinal products have been reported to cause severe adverse reactions due to their adulteration. PDE-Sis, sibutramine, and fenfluramine are common examples of adulterants found in HMPs that have led people to be hospitalized. With LC-MS and combined methods, it is becoming easier to detect adulterants and confirm their presence. However, in order to use these techniques, products have to be brought to the laboratories for screening. Due to this inconvenience and the growth of the HMP market, the need for mobile screening techniques is becoming increasingly more apparent. Attenuated total reflectance-infrared spectrometry and thin-layer chromatography are becoming a necessity in the growing market due to their practicality and quick run time.

Future Perspectives

Zhu et al. [93] have begun to create a finite database for these portable scanning techniques, but this database needs to be expanded. This database could potentially be an online resource categorizing drug classes by characteristics, intensities, and shifts of the analytical techniques. This would make adulteration more difficult for botanical product manufacturers while keeping the consumers safe.

Another important future perspective is the ongoing expansion of the USP Food Fraud Database and the development of the USP Dietary Supplement Adulteration Database. These are repositories of international food and dietary supplement ingredients fraud reports and are associated with analytical techniques, which will facilitate fraud-food-ingredients-dietary supplements. The American Botanical Council and the Food Protection and Defense Institute sponsor the U.S. Pharmacopeial Conference. This experience allows the attendees to learn about fraud and adulteration in food products and dietary supplements. The ABC-AHP-NCNPR Botanical Adulteration Program from the American Botanical Council continues to support educational activities to prevent the adulteration of HMPs.

The FDA has also made a requirement for the supplement marketers to report all adverse reactions. The American Herbal Products Association (AHPA) has made the push over the last several years and is still making the supplement industry more transparent to consumers.

Among the European initiatives to prevent adulteration of HMPs, Rapid Alert System for Food and Feed (RASFF) provides an efficient mechanism to identify adulterations so that different EU member states can take immediate actions on the corresponding products. The HMP market, the need for mobile screening techniques is becoming increasingly more apparent. Attenuated total reflectance-infrared spectrometry and thin-layer chromatography are becoming a necessity in the growing market due to their practicality and quick run time.

Acknowledgements

A.I.C. is indebted to the Harrison School of Pharmacy for the financial support through New Faculty Start Up, and Nature’s Sunshine Inc. for supporting our research on the quality of botanical dietary supplements. M.P.G. acknowledges support from the SENACYT SNI program.

Conflict of Interest

The authors do not have any conflict of interest.

References


Calahan J et al. Chemical Adulterants in... Planta Med 2016; 82: 505–515


74 de Carvalho LM, Correia D, Garcia SC, de Bairros AV, do Nascimento PC, Bohrer D. A new method for the simultaneous determination of 1,4-benzodiazepines and amfepramone as adulterants in phytotherapeutic formulations by voltammetry. Forensic Sci Int 2010; 202: 75–81


95 Zhu Q, Cao Y, Cao Y, Chai Y, Lu F. Rapid on-site TLC-SERS detection of four antidiabetes drugs used as adulterants in botanical dietary supplements. Anal Bioanal Chem 2014; 406: 1877–1884


